Caplin Point Laboratories Share Price
Sector: Biotechnology & Drugs
2087.30 +9.35 (0.45%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2075.05
Today’s High
2153.70
52 Week Low
1370.00
52 Week High
2636.00
2084.00 +3.80 (0.18%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2075.00
Today’s High
2156.80
52 Week Low
1365.00
52 Week High
2641.00
Key Metrics
- Market Cap (In Cr) 15838.86
- Beta 0.75
- Div. Yield (%) 0.14
- P/B 5.54
- TTM P/E 28.34
- Peg Ratio 1.38
- Sector P/E 22.67
- D/E 0
- Open Price 2081.5
- Prev Close 2077.95
Caplin Point Laboratories Analysis
Price Analysis
-
1 Week1.47%
-
3 Months3.49%
-
6 Month-13.29%
-
YTD-16.81%
-
1 Year50.7%
Risk Meter
- 48% Low risk
- 48% Moderate risk
- 48% Balanced Risk
- 48% High risk
- 48% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 2
- 2
- 2
- 2
Caplin Point Laboratories News
Q4 results today: ITC Hotels, Cochin Shipyard, JSW Energy and more on May 15
1 min read . 15 May 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 13 May 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 20 Feb 2025Caplin Point Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 1937.47
- Selling/ General/ Admin Expenses Total
- 177.72
- Depreciation/ Amortization
- 65.96
- Other Operating Expenses Total
- 341.98
- Total Operating Expense
- 1356.5
- Operating Income
- 580.97
- Net Income Before Taxes
- 676.78
- Net Income
- 536.31
- Diluted Normalized EPS
- 70.25
- Period
- 2025
- Total Assets
- 3208.58
- Total Liabilities
- 358.09
- Total Equity
- 2850.49
- Tangible Book Valueper Share Common Eq
- 373.3
- Period
- 2025
- Cashfrom Operating Activities
- 432.37
- Cashfrom Investing Activities
- -334.73
- Cashfrom Financing Activities
- -38.32
- Net Changein Cash
- 60.75
- Period
- 2024
- Total Revenue
- 1694.1
- Selling/ General/ Admin Expenses Total
- 305.11
- Depreciation/ Amortization
- 53.44
- Total Operating Expense
- 1195.18
- Operating Income
- 498.92
- Net Income Before Taxes
- 564.43
- Net Income
- 457.09
- Diluted Normalized EPS
- 59.97
- Period
- 2024
- Total Assets
- 2698.12
- Total Liabilities
- 382.41
- Total Equity
- 2315.71
- Tangible Book Valueper Share Common Eq
- 303.28
- Period
- 2024
- Cashfrom Operating Activities
- 318.39
- Cashfrom Investing Activities
- -320.04
- Cashfrom Financing Activities
- -38.07
- Net Changein Cash
- -38.86
- Period
- 2023
- Total Revenue
- 1466.73
- Selling/ General/ Admin Expenses Total
- 266.98
- Depreciation/ Amortization
- 44.99
- Total Operating Expense
- 1069.96
- Operating Income
- 396.77
- Net Income Before Taxes
- 451.35
- Net Income
- 376.26
- Diluted Normalized EPS
- 49.22
- Period
- 2023
- Total Assets
- 2191.4
- Total Liabilities
- 310.92
- Total Equity
- 1880.48
- Tangible Book Valueper Share Common Eq
- 246.28
- Period
- 2023
- Cashfrom Operating Activities
- 271.37
- Cashfrom Investing Activities
- -217.58
- Cashfrom Financing Activities
- -28.17
- Net Changein Cash
- 26.8
- Period
- 2022
- Total Revenue
- 1269.41
- Selling/ General/ Admin Expenses Total
- 233.31
- Depreciation/ Amortization
- 46.9
- Total Operating Expense
- 921.33
- Operating Income
- 348.08
- Net Income Before Taxes
- 385.82
- Net Income
- 299.84
- Diluted Normalized EPS
- 39.25
- Period
- 2022
- Total Assets
- 1736.32
- Total Liabilities
- 252.39
- Total Equity
- 1483.93
- Tangible Book Valueper Share Common Eq
- 194.37
- Period
- 2022
- Cashfrom Operating Activities
- 336.75
- Cashfrom Investing Activities
- -270.94
- Cashfrom Financing Activities
- -40.71
- Net Changein Cash
- 25.01
- Period
- 2021
- Total Revenue
- 1061.29
- Selling/ General/ Admin Expenses Total
- 186.89
- Depreciation/ Amortization
- 36.97
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 769.02
- Operating Income
- 292.27
- Net Income Before Taxes
- 313.62
- Net Income
- 242.27
- Diluted Normalized EPS
- 31.81
- Period
- 2021
- Total Assets
- 1363.61
- Total Liabilities
- 177.79
- Total Equity
- 1185.82
- Tangible Book Valueper Share Common Eq
- 155.8
- Period
- 2021
- Cashfrom Operating Activities
- 265.77
- Cashfrom Investing Activities
- -5.36
- Cashfrom Financing Activities
- -23.98
- Net Changein Cash
- 236.2
- Period
- 2020
- Total Revenue
- 863.2
- Selling/ General/ Admin Expenses Total
- 118.82
- Depreciation/ Amortization
- 31.62
- Total Operating Expense
- 634.75
- Operating Income
- 228.45
- Net Income Before Taxes
- 269.46
- Net Income
- 215.01
- Diluted Normalized EPS
- 28.42
- Period
- 2020
- Total Assets
- 1125.76
- Total Liabilities
- 177.84
- Total Equity
- 947.91
- Tangible Book Valueper Share Common Eq
- 124.64
- Period
- 2020
- Cashfrom Operating Activities
- 44.68
- Cashfrom Investing Activities
- -54.5
- Cashfrom Financing Activities
- 79.77
- Net Changein Cash
- 70.11
- Period
- 2019
- Total Revenue
- 648.69
- Selling/ General/ Admin Expenses Total
- 82.64
- Depreciation/ Amortization
- 23.43
- Other Operating Expenses Total
- 2.21
- Total Operating Expense
- 440.78
- Operating Income
- 207.91
- Net Income Before Taxes
- 226.88
- Net Income
- 176.57
- Diluted Normalized EPS
- 23.23
- Period
- 2019
- Total Assets
- 742.52
- Total Liabilities
- 109.61
- Total Equity
- 632.91
- Tangible Book Valueper Share Common Eq
- 83.41
- Period
- 2019
- Cashfrom Operating Activities
- 83.43
- Cashfrom Investing Activities
- -100.46
- Cashfrom Financing Activities
- 89.79
- Net Changein Cash
- 73.48
- Period
- 2025-03-31
- Total Revenue
- 502.45
- Selling/ General/ Admin Expenses Total
- 46.51
- Depreciation/ Amortization
- 17.04
- Other Operating Expenses Total
- 86.68
- Total Operating Expense
- 351.43
- Operating Income
- 151.02
- Net Income Before Taxes
- 176.67
- Net Income
- 142.57
- Diluted Normalized EPS
- 18.69
- Period
- 2025-03-31
- Total Assets
- 3208.58
- Total Liabilities
- 358.09
- Total Equity
- 2850.49
- Tangible Book Valueper Share Common Eq
- 373.3
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 432.37
- Cashfrom Investing Activities
- -334.73
- Cashfrom Financing Activities
- -38.32
- Net Changein Cash
- 60.75
- Period
- 2024-12-31
- Total Revenue
- 492.96
- Selling/ General/ Admin Expenses Total
- 46.77
- Depreciation/ Amortization
- 16.2
- Other Operating Expenses Total
- 88.55
- Total Operating Expense
- 346.87
- Operating Income
- 146.09
- Net Income Before Taxes
- 177.26
- Net Income
- 138.96
- Diluted Normalized EPS
- 18.19
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 483.1
- Selling/ General/ Admin Expenses Total
- 44.29
- Depreciation/ Amortization
- 16.76
- Other Operating Expenses Total
- 85.23
- Total Operating Expense
- 335.1
- Operating Income
- 148
- Net Income Before Taxes
- 168.46
- Net Income
- 130.8
- Diluted Normalized EPS
- 17.12
- Period
- 2024-09-30
- Total Assets
- 2924.22
- Total Liabilities
- 381.69
- Total Equity
- 2542.53
- Tangible Book Valueper Share Common Eq
- 333.01
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 185.82
- Cashfrom Investing Activities
- -129.95
- Cashfrom Financing Activities
- -18.88
- Net Changein Cash
- 38.14
- Period
- 2024-06-30
- Total Revenue
- 458.96
- Selling/ General/ Admin Expenses Total
- 40.15
- Depreciation/ Amortization
- 15.96
- Other Operating Expenses Total
- 81.52
- Total Operating Expense
- 323.11
- Operating Income
- 135.85
- Net Income Before Taxes
- 154.38
- Net Income
- 123.98
- Diluted Normalized EPS
- 16.32
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 453.22
- Selling/ General/ Admin Expenses Total
- 36.77
- Depreciation/ Amortization
- 16.4
- Other Operating Expenses Total
- 6.13
- Total Operating Expense
- 324.39
- Operating Income
- 128.83
- Net Income Before Taxes
- 146.03
- Net Income
- 121.59
- Diluted Normalized EPS
- 15.9
- Period
- 2024-03-31
- Total Assets
- 2698.12
- Total Liabilities
- 382.41
- Total Equity
- 2315.71
- Tangible Book Valueper Share Common Eq
- 303.28
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 318.39
- Cashfrom Investing Activities
- -320.04
- Cashfrom Financing Activities
- -38.07
- Net Changein Cash
- -38.86
- Period
- 2023-12-31
- Total Revenue
- 435.5
- Selling/ General/ Admin Expenses Total
- 36.67
- Depreciation/ Amortization
- 13.9
- Other Operating Expenses Total
- 66.44
- Total Operating Expense
- 307.12
- Operating Income
- 128.38
- Net Income Before Taxes
- 145.41
- Net Income
- 117.2
- Diluted Normalized EPS
- 15.39
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Caplin Point Laboratories Technical
Moving Average
SMA
- 5 Day2056.95
- 10 Day2080.7
- 20 Day2100.54
- 50 Day2033.58
- 100 Day2002.23
- 300 Day2061.12
Caplin Point Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Alembic Pharmaceuticals
- 974.2
- 0.15
- 0.02
- 1296.15
- 725.6
- 19149.18
- Jubilant Pharmova
- 1176.95
- -1.9
- -0.16
- 1309
- 701.4
- 18760.12
- Caplin Point Laboratories
- 2087.3
- 9.35
- 0.45
- 2636
- 1370
- 15838.86
- Natco Pharma
- 883.75
- 12.05
- 1.38
- 1638.35
- 660.05
- 15828.84
- Sanofi India
- 6180
- 4.95
- 0.08
- 7593.6
- 4145.9
- 14229.2
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Alembic Pharmaceuticals
- 33.51
- 3.68
- 13.54
- 10.84
- Jubilant Pharmova
- 35.29
- 3
- 6.87
- 5.64
- Caplin Point Laboratories
- 30.01
- 5.62
- 21.81
- 26.11
- Natco Pharma
- 8.35
- 2.07
- 18.55
- 30.39
- Sanofi India
- 41.08
- 16.27
- 32.83
- 21.53
Caplin Point Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 15-May-25
- Audited Results & Interim Dividend
- 07-Feb-25
- Quarterly Results
- 07-Nov-24
- Quarterly Results
- 07-Aug-24
- Quarterly Results & Final Dividend
- 16-May-24
- Audited Results & Interim Dividend
- 09-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results, Final Dividend & A.G.M.
- 27-May-23
- Audited Results & Interim Dividend
- 24-May-23
- Audited Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 30-Sept-24
- 07-Aug-24
- AGM
- 21-Sept-23
- 08-Aug-23
- AGM
- 28-Sept-21
- 05-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 15-May-25
- 30-May-25
- 30-May-25
- 3
- 15-May-25
- 30-May-25
- 30-May-25
- 3
- 07-Aug-24
- -
- 23-Sept-24
- 2.5
- 16-May-24
- 31-May-24
- 31-May-24
- 2.5
- 07-Aug-23
- -
- 14-Sept-23
- 2.5
- 29-May-23
- 09-Jun-23
- 09-Jun-23
- 2
- 29-May-23
- 09-Jun-23
- 09-Jun-23
- 2
- 05-Aug-22
- -
- 21-Sept-22
- 2
- 12-May-22
- 24-May-22
- 23-May-22
- 2
- 05-Aug-21
- -
- 20-Sept-21
- 1.5


